Key result
High-dose statin therapy prescribed post-NSTEMI caused severe rhabdomyolysis presenting as flaccid tetraparesis in an 82-year-old woman, resolving after statin discontinuation.
Case Report (n=1)
No
High-dose statin therapy post-NSTEMI can cause severe rhabdomyolysis presenting as flaccid tetraparesis, requiring prompt discontinuation and supportive care.
Answers are grounded in this paper and cite their sources.
High-dose statins warrant caution for rhabdomyolysis with tetraparesis in elderly post-NSTEMI patients; this case leaves open broader risk stratification needs.
An 82-year-old white woman presented at our Internal Medicine ward with flaccid tetraparesis. Two months earlier, she had suffered a non-ST elevation myocardial infarction treated with percutaneous coronary intervention (PCI) and stenting, and she had been prescribed the classical post-PCI therapy (β-blockers, statins and antiplatelet agents). At admission, she was haemodynamically stable and the physical examination revealed reduced reflexes in the four limbs. Urgent laboratory findings revealed mild hypokalaemia. Considering the high statin doses she was taking, we also performed an urgent creatine phosphokinase test, which indicated rhabdomyolysis. Statin therapy was immediately stopped and aggressive fluid treatment begun, supplemented with potassium for increased urinary potassium losses. The patient progressively regained muscle strength.
No takes yet. Share an insight, caveat, or question.
Rosada et al. (2015) conducted a case report in Statin-induced rhabdomyolysis (n=1). Statin therapy was evaluated on Development of flaccid tetraparesis and rhabdomyolysis. High-dose statin therapy prescribed post-NSTEMI caused severe rhabdomyolysis presenting as flaccid tetraparesis in an 82-year-old woman, resolving after statin discontinuation.
Synapse has enriched 10 related papers. Consider them for comparative context: